15 May WisBusiness: Cellectar Biosciences is reporting the best outcomes yet from an ongoing Phase 1 clinical trial of the Madison company’s cancer therapy drug
Data from the sixth cohort of patients in the clinical trial shows a 50 percent partial response rate, a 50 percent minimal response rate, and a 100 percent disease control rate.
“We are observing a clear dose response with greater and more prolonged median reductions in surrogate efficacy markers throughout the study safety evaluation period as compared to prior cohorts,” said James Caruso, president and CEO of Cellectar.
The independent data monitoring committee that oversees the company’s clinical studies has determined the latest dosing regimen is safe and tolerable. With that approval, Cellectar has started a seventh cohort of patients that will receive an elevated dose of the cancer therapy. Data from that cohort is expected in the fourth quarter of this year.
All patients in these cohorts have advanced forms of multiple myeloma, a cancer of the body’s plasma cells.
Read the article here.